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The hepatic transport of the immunosuppressive Cyclosporin A (CyA) was
studied using liposomal phospholipid membranes, freshly isolated rat hepato-
cytes and bile canalicular plasma membrane vesicles from rat liver. The Na+-
dependent, saturable uptake of the bile acid 3H-taurocholate into isolated rat
liver cells was apparently competitively inhibited by CyA. However, the uptake
ofCyA into the cells was neithersaturable, nortemperature-dependent norNa+-
dependent, nor could it be inhibited by bile salts or CyA-derivatives, indicating
passive diffusion.
In steady statedepolarization fluorescence studies, CyA caused a concentration-
dependent decrease of anisotropy, indicating a membrane fluidizing effect. Ion
flux experiments demonstrated that CyA dramatically increases the permeabil-
ity ofNa+ and Ca2+ across phospholipid membranes in a dose- and time-depen-
dent manner, suggesting a iontophoretic activity that might have a direct impact
on cellular ion homeostasis and regulation ofbile acid uptake.
Photoaffinity labeling with a [3H]-labeled photolabile CyA-derivative resulted
in the predominant incorporation of radioactivity into a membrane polypeptide
with an apparent molecular weight of 160,000 and a minor labeling ofpolypep-
tides with molecular weights of85,000-90,000. In contrast, use ofa photolabile
bile acid resulted in the labeling of a membrane polypeptide with an apparent
molecular weight of 110,000, representing the bile canalicular bile acid carrier.
The photoaffinity labeling as well as CyA transport by canalicular membrane
vesicles were inhibited by CyA and the p-glycoprotein substrates daunomycin
and PSC-833, but not by taurocholate, indicating that CyA is excreted by p-gly-
coprotein. CyA uptake by bile canalicular membrane vesicles was ATP-depen-
dent and could not be inhibited by taurocholate. CyA caused a decrease in the
maximum amount ofbile salt accumulated by the vesicles with time. However,
initial rates of [3H]-taurocholate uptake within the first 2.5 min remained
unchanged at increasing CyA concentrations.
In summary, the data indicate that CyA does not directly interact with the hepat-
ic bile acid transport systems. Its cholestatic action may rather be the result of
alterations in membrane fluidity, intracellular effects and an interaction with p-
glycoprotein.
INTRODUCTION
The immunosuppressive peptide Cyclosporin A (CyA)c (Sandimmun® [1]) is of spe-
cial interest, because of its early use in the long-term treatment of autoimmune diseases
and the prevention of allograft rejection after organ transplantation [1-3]. Its clinical
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administration requires cautious monitoring due to various side effects. In addition to
nephrotoxicity, increased bilirubin plasma levels and elevated serum bile salt levels have
been reported from animals and patients receiving the drug [4-10], indicating cholestatic
effects ofCyA or its metabolites. In recent studies inhibition ofbile salt biosynthesis was
suggested as an explanation for the cholestatic effects seen at CyA treatment [11].
However, increased plasma levels oftransaminases have not been reported [5, 6, 12, 13],
indicating a transport defect rather than a general cellular impairment. An interference of
CyA with the transport of bile acids is discussed controversially. With isolated rat hepa-
tocytes nonspecific binding of CyA to protein components of a postulated cholate trans-
port system without uptake by this system was observed [14], whereas competitive and
noncompetitive inhibition of taurocholate uptake by CyA has been seen in membrane
vesicle experiments [15, 16].
To shed light on these controversies, a study was performed on the hepatic uptake and
excretion of CyA using different experimental models such as liposomal phospholipid
membranes, freshly isolated rat hepatocytes, and bile canalicular plasma membrane vesi-
cles from rat liver.
MATERIALS AND METHODS
Chemicals
All cyclosporins were from Sandoz Pharma AG, Basle, Switzerland. [6-3H]-tauro-
cholate (Na+-salt) with a specific activity of6.6 Ci/mmol was obtained from DuPont-New
England Nuclear(Dreieich, Germany). 22NaCl with a specific activity of500mCi/mgNa+
was purchased from Amersham (Buckinghamshire, UK). 1,6-diphenyl-1,3,5-hexatriene
(DPH) was from Molecular Probes, Inc. (Eugene, OR). All other substances were
obtained at the highest purity from commercial sources.
Isolation ofhepatocytes
Isolated hepatocytes from livers ofmaleWistar rats were prepared by a modified col-
lagenase perfusion technique [17]. The cells were suspended in Krebs-Henseleit-medium
at a concentration of 2-3 x 106 cells/ml. They were allowed to recover for approximately
30 min by gently shaking them under a carbogen (95 percent 02/5 percent CC2) atmos-
phere at 37°C before all uptake studies. The viability of the cells was estimated after the
isolation procedure and a second time after the transport experiments by determination of
Trypan blue exclusion and leakage of lactate dehydrogenase. Only cells with a viability
greater than 90 percent were used for transport experiments. All experiments with freshly
isolated cells were performed within 2 hr after hepatocyte isolation.
Transport experiments with isolated hepatocytes
Uptake of radiolabelled CyA and taurocholate into freshly isolated hepatocytes was
measured at 37°C by a rapid centrifugation technique [18, 19]. The concentration of the
CyA varied between 0.1 and 10 ,uM dependent upon the extreme low solubility in aqueous
solutions, the bile salt concentration ranging from 0.1 to 250 gM. CyA was added to the
incubation media from stock solutions ofDMSO to obtain a final solvent concentration not
higher than 1 percent (v/v). The solvent was also added in reference measurements with-
out CyA. Control experiments (bile salt uptake measurements) showed no difference in
uptake rates. Initial rates of uptake into isolated hepatocytes were calculated from the
slopes in the linear range by linear regression analysis, considering only data points with-
in the first 60 sec ofuptake (15 sec intervals). The kinetic parameters were analyzed by the
non-linear least-square regression analysis program Enzfitter 1.05 (Elsevier-Biosoft,
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Cambridge, UK). The resulting kinetic data are reported as means ± SE. Statistic differ-
ences were determined by use ofthe appropriate paired or unpaired t-test.
Isolation ofbile canalicularplasma membrane vesicles
Canalicular liverplasma membrane subfractions were isolated in high yield by acom-
bination of rate zonal and discontinuous sucrose density gradient centrifugation as
described in detail [20, 21]. Membrane vesicles were resuspended in the appropriate
buffer media (see corresponding figure legends), and aliquots were stored frozen in liquid
nitrogen until use.
Transport measurements with bile canalicularplasma membrane vesicles
Transport determinations in the presence and absence ofATP were determined by the
rapid filtration assay following generally the recently described experimental protocols
[22]. The exact initial compositions of the intravesicular buffers as well as of the extrav-
esicular media are described in the respective figure legends. At the indicated time points,
the uptake of radioactive substrate was stopped by addition of twice 2 ml ice-cold stop
solution (50 mM sucrose, 100 mM KCl, 10 mM MgSO4, 10 mM Tris/HCl, pH 7.4). After
an additional washing step, the vesicle-associated radioactivity on the filters was deter-
mined by liquid scintillation counting as described [22].
Photoaffinity labeling ofbile canalicular membranes
Membrane vesicles were resuspended in 50 mM sodium phosphate buffer, pH 7.4.
Aliquots of250 jl (-0.3- 0.5 mg protein) were incubated with the sodium salt of7,7 azo-
3a,12cz-dihydroxy-5B-[3B-3H]cholan-24-oyl)-2-aminoethanesulfonic acid or the photola-
bile CyA derivative (1 ,uM) for 3 min in the dark at 25°C. Photolysis was carried out at
300 or 350 nm for 5 min in arotating cylindrical cuvette made ofquartz glass in a Rayonet
RPM 100 photoreactor (New England Ultraviolet, Hamden, Connecticut). The unbound
radioactive derivatives were removed by centrifugation of the membrane suspension at
50,000 x g for 30 min. The membrane proteins were separated by SDS-polyacrylamide
gel electrophoresis and the radioactivity incorporated into the various protein bands was
determined as previously described [20].
Liposome preparation
Liposomes for binding and fluorescence experiments were prepared by the extrusion
technique, as described previously [23]. Dioleyl-phosphatidylcholine was used as phos-
pholipid. The distribution ofliposome size was determined by laser light scattering at900
with a ZetaSizer III (Malvern Instruments, London, UK).
Partition coefficient measurements
Appropriate amounts of CyA were dried from stock solutions in chloroform into
Eppendorftubes. One milliliter ofliposome suspension (total lipid = 10 mg) was added to
the vial and shaken for 2 hours. Concentrations of CyA in the liposomal solution were
between 12 and 320 ,uM. Centrifugation tubes were equilibrated over night with a corre-
sponding aqueous concentration to avoid excessive adsorption of CyA to the tube. The
suspension was centrifuged in a Beckman Ultracentrifuge TL-100 at 198,000 rpm for 6 hr
at 25°C. The lipid content was measured by a phospholipase-D/cholinoxidase/PAP-test
(WAKO Chemicals GmbH, Neuss, Germany). CyA concentration in supernatant and pel-
let was measured by a radioimmunoassay (detection limit: 15 ng/ml).
Fluorescence measurements
Steady state fluorescence measurement were performed with a Perkin-Elmer LS5OB
instrument (Perkin Elmer Inc. Basle, Switzerland) equipped with polarization and Biokin
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accessories. The cuvette holder was controlled by a Julabo FIO thermostat (Merck ABS,
Switzerland) at 25°C. Excitation was done at 336 nm (3 nm slit width), emission was
determined over a 10-second integration at 430 nm (3 nm slit width). DPH was added to
the liposomal suspension to give a molar lipid:DPH ratio of 200 in a buffer system of 50
mM NaCl, 50 mM KCl, 20 mM Tris, pH 7.4. The LS-50B software allowed the calcula-
tion ofanisotropy with G-factor correction.
Ionflux measurements
Liposomes were suspended in 60gl buffer containing 150 mM NaCl, 30 mM imida-
zole, 5 mM MgSO4, 1 mM EDTA, pH 7,2 and 2 ,uCi 22NaCl. The suspensions were pre-
equilibrated with CyA. For that reason, 1 to 4gl of the test compound stock solution (10
mM in ethanol:H20) was added to 60 ,ul liposomes in different test vials.As control exper-
iment, the same amount ofethanol:H20 without test compound was added to 60gl ofthe
liposome suspension. The flux experiments were performed at 20-23°C.
An ion exchange resin (Bio-Rex 70) was equilibrated for at least one day with 1 mM
Tris, pH 7.4. For at least two days the resin was re-equilibrated with 0.15 M Tris, pH 7.4.
After filling the microcolumns with the resin, the columns were washed with 2 ml of the
appropriate iso-osmolar sucrose solution, containing 342 mM sucrose, 20 mM Tris, pH
7.2 forNa+-flux measurement. The prepared microcolumns could be stored at4°C for sev-
eral days.
The liposomes were added to the radioactive test compound, thoroughly mixed and
kept at room temperature or at 37°C. At different times (O hr to 150 hr) 6 gl of the lipo-
some suspension was added to 60 gl ofcold (0-2°C) iso-osmolar sucrose and mixed well.
From that mixture, 28 pl aliquots were layered on the cooled microcolumns. The lipo-
somes from the sample were directly eluted with 1 ml cold (0-4°C) iso-osmolar sucrose
into a scintillation counting vial. Four ml ofscintillation fluid were added and the radioac-
tivity was measured for 60 min or until the relative standard deviation was less than 0.4
percent. As control experiment, 5 ml of the liposome-sucrose mixture was mixed with 1
ml of sucrose and the radioactivity was determined.
RESULTS
Cellular uptake studies
The saturable uptake oftaurocholate into freshly isolated hepatocytes was decreased
in the presence of increasing concentrations ofCyA in the incubation medium. The type
of inhibition was apparently competitive (Figure 1). The transport of CyA isolated rat
hepatocytes was determined in the concentration range from 0.1 uM to 10 gM. Higher
concentrations resulted in visible precipitation of the cyclopeptide due to its highly
lipophilic character. After a rapid concentration dependent absorption within the first 2 to
3 sec the uptake was linear over the whole time interval of investigation (up to 5 min).
When the initial rates ofuptake, derived from linear regression ofthe values for cell asso-
ciated radioactivity between 15 sec and 60 sec, were plotted as a function of increasing
concentrations, no marked deviation from linearity could be observed, indicating that the
uptake occurs by passive diffusion (Figure 2). The diffusion coefficient of CyA was 0.50
± 0.02 x 10-4 1/min/mg protein. The uptake was neither Na+-dependent as was tauro-
cholate uptake, nor temperature dependent. The transport of CyA could not be inhibited
by taurocholate at concentrations up to 100 FM (Figure 2).
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Figure 1. Initial rates ofuptake of[3H]-taurocholate intofreshlyisolated rathepatocytes in the
absence (@) and in the presence of0.5 ,uM CyA (A) or 5.0 uM CyA (0) (n = 6; means ± S.E.).
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Figure 2. Initial rates of
uptake of [3H]-CyA into
freshly isolated rat hepato-
cytes in the absence (0) or
in the presence (0) of 100
gM cholyltaurine (n = 6;
means ± S.E.).
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Cyclosporin-induced changes in physicochemical membrane properties
The lipophilicity of CyA was determined by measuring the partition coefficient
between liposomal membranes and buffer. The partition coefficient for CyA was 4034 ±
521 (mean ± SD, n = 20). In addition, liposomal membrane anisotropy was determined.
In steady-state depolarization fluorescence studies, Dioleyl-phosphatidylcholine lipo-
somes were incubated with increasing amounts of CyA in the concentration range
between 0.5-10 ,uM. CyA caused a pronounced concentration-dependent decrease of
anisotropy (Figure 3), indicating a membrane-fluidizing effect (decrease of 46 percent
measured at 25°C at a lipid:drug ratio of 13:1). Furthermore, Na+ and Ca2+_fluxes across
liposomal membrane were determined. The permeability ofliposomal membranes forNa+
and Ca2+ ions was dramatically increased in a dose- and time-dependent manner in the
presence of CyA (Figure 4), suggesting an ionophoric activity of the latter.
0,075 Figure 3. Steady state
fluorescence anisotropy
0,070 - of DOPC liposomes incubated with different
amounts ofcyclosporins.
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_: 0060- \ mM NaCl, 50 mM KCl,
20 mM Tris; pH 7.4) were
2 ~ 0055 preincubated with DPH
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lipid:DPH = 200:1) for
> 0,050-\ about 1 hr. CyA was
2 added from a 100 mM
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c* 0,045- Measurements (excitation XD \336 nm, emission 430 nm,
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not show any significant
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Photoaffinity labeling studies with bile canalicular membrane vesicles
Photoaffinity labeling ofbile canalicular membrane vesicles from rat liver with a pho-
tolabile 3H-labelled CyA-derivative resulted in the incorporation of radioactivity into a
polypeptide with apparent molecular weight of approximately 160,000 and in a minor
labeling ofpolypeptides in the molecular weight range of 85,000-90,000 (Figure Sa). The
extent of labeling of the polypeptide with the apparent molecular weight of 160,000 was
reduced when the experiment was performed in the presence of unlabeled CyA or in the
presence ofPSC-833, a potent inhibitor ofp-glycoprotein. Taurocholate (100 ,uM) had no
effect on the extent of the labeling (Figure Sa). In contrast, when a photolabile bile salt
derivative [Na+-salt of (7,7 azo-3a,12a-dihydroxy-5B-[3B-3H]cholan-24-oyl)-2-amino-
ethanesulfonic acid] was used, the canalicularbile saltcarrierprotein with an apparentmol-
ecular weight of 110,000 was almost exclusively labeled. The extent of this labeling was
only slightly reducedby 0.5 - 5 FM CyA. A significantly lower extent oflabeling was seen,
when the experiment was performed in the presence of 100 jM taurocholate (Figure Sb).
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Figure 4. A (upper): Time dependent Na+-flux measurements with liposomes loaded with 480 ,uM
CyA (@); 0 = blank. B (lower): Time dependent Ca2+-flux measurements with liposomes loaded
with 500 ,uM CyA (0); 0 = blank. The given concentrations ofCyA are concentrations in the total
lipid suspension; the concentrations in the aequous solution were approximately 20gM. Error bars
are covered by the symbols.
Kinetic studies were performed in order to support the photoaffinity labeling experi-
ments and to clarify whether CyA only binds to membrane proteins or whether it is a
transported substrate. When uptake of CyA was studied, the bile canalicular membrane
vesicles showed an ATP-dependent transport (Figure 6), which could be inhibited by
daunomycin, a p-glycoprotein substrate. Taurocholate had only minor effects upon CyA
uptake rates in the vesicles. When theATP-dependent transport of [3H]-taurocholate was
determined, the presence of CyA resulted in a decrease of the maximum amount of bile
salt accumulated in the vesicles with time. However, the initial rates of [3H]-taurocholate
uptake within the first 2.5 min of determination remained unchanged at increasing CyA
concentrations (Figure 7).
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Figure 5. A (upper): Photoaffinity labeling of bile canalicular membrane vesicles from rat liver
with a photolabile [3H]-CyA-derivative in the absence of 100 jM taurocholate (0) and in the pres-
ence of 100 jM taurocholate (0), 1O ,uM non-immunosuppressive PSC-833 (A) or 10 jM CyA (A).
The photolabile compound is predominantly incorporated into a polypeptide with apparent molec-
ular weights of 160,000. B (lower): Photoaffinity labeling of bile canalicular membrane vesicles
from rat liver with a photolabile [3H]-taurocholate derivative in the absence (0) or in the presence
of 100 jM taurocholate (0). The bile salt is almost exclusively incorporated into a polypeptide with
an apparent molecular weight of 110,000.
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DISCUSSION
Cyclosporin A, a cyclic undecapeptide produced by the fungus Tolypocladium infla-
tum Gams, is a powerful immunosuppressant drug [1], which selectively inhibits the inter-
leukin-2 (IL-2)-driven proliferation of activated T-lymphocytes. The pharmacokinetics of
CyA exhibit a high inter- and intraindividual variability, which is dependent upon various
factors such as food interactions, influence of bile, and physicochemical parameters, e.g.,
the high lipophilicity or differences in drug metabolism caused by the patient's metabolic
situation [24]. The immunosuppressive therapy may be associated with adverse effects
including renal dysfunction, vascular damage and hepatic side effects [5, 25]. CyA-
induced increases of serum bile acid levels in animal and man [10, 12, 26] are indicative
for a certain cholestatic potential. Since the data on hepatic transport of CyA are contro-
versial [14-16], we investigated the transport ofthat important drug in more detail in sev-
eral in vitro models.
CyA has a unique lipophilicity making effects upon cellular membranes most likely,
for example, the anisotropy decrease correlates with a dramatic increase ofthe membrane
permeability of Na+ and Ca2+. Both effects, the changes in membrane fluidity as well as
in ion homeostasis, may contribute to the decrease ofhepatic bile acid uptake during CyA
trealtment by disturbing the transmembrane potential and cellular ion gradients. Similar
effects have also been observed in other cellular systems [27, 28]. In human lymphocytes
CyA caused an enhanced K+ efflux and reduced the membrane potential. Therefore it is
likely, that such alterations in membrane integrity also contribute to CyA-induced distur-
bances of liver function.
The increase of serum bile acid levels in patients observed during CyA-treatment
indicates a disturbance of hepatic bile acid transport. In our study, CyA had a pronounced
effect on taurocholate uptake with an apparently competitive type of inhibition. For the
present, this confirms previous findings with rat hepatocyte basolateral plasma mem-
branes and hepatocyte primary cultures, where a competitive inhibition was also observed
[15, 29]. However, CyA itselfshowed no sign ofactive uptake by isolated rat hepatocytes.
Therefore, we conclude that the inhibition of bile acid transport is the result of an unspe-
cific binding, the observed disturbance in ion homeostasis, and a simple rapid partitioning
into the lipid phase. The present finding is supported by findings in isolated intact kidney
tubules, where a passive uptake of cylcosporins from the basolateral side and an active
secretion at the luminal side was observed [30].
Previous studies indicated that CyA is a potent inhibitor ofATP-dependent transport
processes at the canalicular membrane including p-glycoprotein mediated transport [31-
34]. Here, we demonstrate that CyA itselfcan be transported across bile canalicular mem-
branes by an active, ATP-dependent mechanism. The photoaffinity labeling experiment
and the kinetic experiment give clear evidence that it is a substrate for p-glycoprotein. The
labeling was decreased in the presence unlabeled CyA and ofthe p-glycoprotein substrate
PSC-833, which is a non-immunosuppressive cyclosporin derivative with a very high
affinity to p-glycoprotein [35-37]. Our findings are in accordance with kinetic and pho-
toaffinity labeling experiments in kidney tubular cells [30, 38, 39], kinetic studies with the
intestinal cell line Caco-2 [40] and at the brain capillary endothelium [41], all cell types
expressing p-glycoprotein and exhibiting active CyA transport at their luminal side. The
fact, that the initial rates of bile acid transport by the canalicular membrane vesicles
remain unchanged over the first 2.5 min, suggests that CyA transport results rather in a
faster use ofthe cellular ATP pool than in a direct competition ofthe drug at the bile acid
carrier.
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SUMMARY
The present studies indicate that CyA enters hepatocytes by passive diffusion and is
secreted by p-glycoprotein. Inhibition of bile salt transport does not occur due to a spe-
cific interaction. For an estimation ofthe clinical relevance ofthese findings, the pharma-
cokinetic properties of CyA should be verified in primate or human studies with empha-
sis on the p-glycoprotein interaction of the drug.
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